Complement is an acute-reacting non-specific effector system. Activation and consumption of individual components of this multicomponent system occur secondarily to specific complement fixing events. The complement system is therefore an indirect and imprecise diagnostic tool and can be used clinically only as a general indicator of the severity of a particular disease or as a monitor of its progress. An exception is the case of the very rare inherited complement deficiencies where examination of the system does become directly diagnostic.
The 11 proteins of the classical pathway, three additional ones of the alternative pathway, and three natural inhibitors can be measured either immunochemically using the appropriate specific antibody or functionally by the appropriate haemolytic assay. At present only a limited number of activation and consumption profiles can be considered to be clinically useful.
Immune complex diseases
The commonest changes are those seen in overt circulating immune complex disease where the early components of the classical pathway Cl, C4, C2, and C3 are variably but often much reduced when measured by both immunochemical and haemolytic titration. Haemolytic C6 and C7 almost never fall outside the normal range, though CS may be reduced. The prime example of a disease demonstrating this profile is clinically severe systemic lupus erythematosus (SLE) when it presents or during relapse, and identical changes are seen in some cases of mixed connective tissue disease and rheumatoid vasculitis (Table 1) . Some investigators (West et al., 1973; Whaley et al., 1979) have shown marked falls in factor B, properdin, and the control protein /1H in active SLE, and they interpret these findings as evidence for triggering of the feedback cycle in such cases.
The immune complex profile of complement consumption is seen in several infectious diseases and is particularly associated with a 'serum sickness'-like phase of the infection (Alpert et al., 1971; Meyer zum Buschenfelde et al., 1978) . Not surprisingly, Table 1 . C1423 complement component consumption is an almost invariable accompaniment of poststreptococcal nephritis and shunt nephritis (Strife et al., 1976; Harkiss et al., 1979) , though in poststreptococcal nephritis there is often a disproportionate fall in C3 and CA concentrations in relation to Cl and C2 (West et al., 1973) .
The incidence of these changes in the other examples in Table 1 is not yet established since it is based on small numbers of observations by the author and others. Complement changes suggestive of classical pathway activation occur at the time of the serum sickness-like illness reported to develop 5-10 days after meningococcal or gonococcal septicaemia (Greenwood et al., 1976) . A rather different association between neisserial infections and complement occurs in rare patients with inherited total deficiencies of C6, C7, or C8. 'Classical' serum sickness with pronounced C1423 consumption is still occasionally seen and can, for example, follow the injection of heterologous antisnake venom serum (Nielsen et al., 1978 Table 2 . Several other cases (Marder et al., 1976; Geha and Akl, 1976) (Marder et al., 1978) . But there seems to be some overlap between this syndrome and other cases presenting with chronic urticaria, arthritis, and leucocytoclastic venulitis which have typical Cl, C4, C2 and C3 consumption, variable amounts of circulatory immune complexes, and cryoglobulins (McDuffie et al., 1973; Soter et al., 1974; Soter, 1977) . (Ruddy et al., 1975 (Perrin et al., 1975; Laurell et al., 1978; Thompson et a!., 1978) .
Nephritic factor and mesangiocapillary glomerulonephritis
A disease with a unique complement consumption profile is the form of mesangiocapillary glomerulonephritis clinically associated with partial lipodystrophy and histologically associated with intramembranous dense deposits in the glomerular basement membranes. Most of the patients have very low though not absent C3, normal or low immunochemical factor B levels, low haemolytic factor B levels, and increased catabolic rates for C3 and factor B (Charlesworth et al., 1974; Sissons et al., 1976) . Other complement components including Cl, C4, and C2 are normal (Thompson and White, 1973 (Davis et al., 1977; Scott et al., 1978) . The presence of nephritic factor is usually demonstrated in a simple assay in which, on mixing with normal serum, it converts native C3 (P1C) to C3c (,81A). The conversion products are detected by Laurell electrophoresis.
Inherited complement deficiencies
Many of the patients with these deficiencies suffer from diseases secondary to the deficiency state. Homozygous Cl, C4, and C2 deficient patients present with SLE, SLE-like syndromes, or moderate to severe glomerulonephritis. In individual cases followed for some time it appears that during disease activity (Day et al., 1973) (Thompson and Lachmann, 1977 (Donaldson and Rosen, 1964) . C3 levels remain normal, an observation which allows clear distinction between angioedema and immune complex diseases. A secondary angioedema syndrome (Caldwell's syndrome) is now recognised as a rare complication of lymphoma, chronic lymphocytic leukaemia, and macroglobulinaemia (Caldwell et al., 1972; Day et al., 1976; Schreiber et al., 1976; Casali et al., 1978) . Cl esterase inhibitor falls to low levels, apparently stoichiometrically consumed by excessive amounts of active Cl which, in turn, is fixed and activated by an unusual cold-reacting antigen-antibody complex. In both the primary and secondary syndrome the definitive diagnosis rests on finding functionally low (less than 30 %) or absent Cl esterase inhibitor.
Gram-negative septicaemia
Many agents apparently activate complement by antibody-independent mechanisms, though so far the mode of action of most of these agents has been evaluated only by in-vitro tests. In-vivo studies of antibody-independent complement changes have been limited to lipopolysaccharides (endotoxins) and in man in particular to changes observed in Gramnegative septicaemia. Although the haemodynamic changes which accompany Gram-negative septicaemia are complex and ill understood, a few experimental clinical studies have attempted to correlate alternative pathway activation and consumption with shock and mortality. However, there has been little general attempt by clinicians to use complement changes as a prognostic indicator. Recently, Whaley and colleagues (unpublished) have shown significant correlations between falls in C3, factor B, and the alternative pathway control protein f31H and an unfavourable outcome in Gram-negative septicaemia.
